BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
See today's BioWorld
Home
» ASCO20: Adaptimmune updates work at T-cell frontier; SPEAR in high gear, ASCO hears
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ASCO20: Adaptimmune updates work at T-cell frontier; SPEAR in high gear, ASCO hears
June 1, 2020
By
Randy Osborne
No Comments
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) rocketed to $11.07 Friday, up $127% or $6.21, on updated data rolled out at the American Society of Clinical Oncology (ASCO) meeting, held virtually this year.
BioWorld
Conferences
American Society of Clinical Oncology
Cancer